Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: Studies with the antagonist exendin 9-39

Diabetes

Volumn 48, Issue 1, 1999, Pages 86-93

  Edwards, C Mark B ^a   Todd, Jeannie F ^a   Mahmoudi, Mehdi ^a   Wang, Zhili ^a   Wang, Ren Ming ^a   Ghatei, Mohammad A ^a   Bloom, Stephen R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN[9-39]; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 ANTAGONIST; GLUCOSE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING;

CYTOKINES; EATING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; ISLETS OF LANGERHANS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 0032960834     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.1.86     Document Type: Article

References (49)

1. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF: Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261:11880-11889, 1986
2. Varndell IM, Bishop AE, Sikri KL, Uttenthal LO, Bloom SR, Polak JM: Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry. J Histochem Cytochem 33:1080-1086, 1985
3. Orskov C: Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35:701-711, 1992
4. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon like peptide 1 (7-36): a physiological incretin in man. Lancet ii:1300-1303, 1987
5. McIntyre N, Holdsworth DC, Turner DS: New interpretation of oral glucose tolerance. Lancet ii:20-21, 1964
6. Creutzfeldt W: The incretin concept today. Diabetologia 16:75-85, 1979
7. Dupre J, Ross SA, Watson D, Brown JC: Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37:826-828, 1973
8. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF: Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 84:3434-3438, 1987
9. Fehmann HC, Habener JF: Insulinotropic hormone glucagon-like peptide-1 (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma betaTC-1 cells. Endocrinology 130:159-166, 1992
10. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Hoist JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673, 1993
11. Nauck MA, Niedereichholz R, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmeigel WH: Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273:E981-E988, 1997
12. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
13. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW: Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266, 1994
14. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J, Bloom SR: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72, 1996
15. Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515-520, 1998
16. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide-1 (7-36) amide but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307, 1993
17. Todd JF, Edwards CMB, Ghatei MA, Mather HM, Bloom SR: Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a three-week period in patients with early type II diabetes. Clin Sci 95:325-329, 1998
18. Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK: The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Reg Pep 51:63-74, 1994
19. Thorens B: Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide-1. Proc Natl Acad Sci U S A 89:8641-8645, 1992
20. Dillon JS, Tanisawa Y, Wheeler MB, Leng XH, Ligon BB, Rabin DH, Yoo-Warren H, Permut MA, Boyd AE: Cloning and functional expression of the human glucagon-like-peptide-1 (GIP-1) receptor. Endocrinology 133:1907-1910, 1993
21. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C: Cloning and 7unctional expression of the human islet GLP-1 receptor demonstration that exendin-4 is an agonist and exendin 9-39 an antagonist of the receptor. Diabetes 42:1678-1682, 1993
22. Raufman JP, Singh L, Singh G, Eng J: Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas: identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem 267:21432-21437, 1992
23. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268:19650-19655, 1993
24. Wang ZL, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR: Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 95:417-421, 1995
25. Kolligs F, Fehmann HC, Goke R, Goke B: Reduction of the incretin effect in rats by the glucagon-like peptide-1 receptor antagonist exendin-(9-39)-amide. Diabetes 44:16-19, 1995
26. D'Alessio DA, Vogel R, Prigeon R, Leschansky E, Koerker D, Eng J, Ensinck JW: Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion in healthy baboons. J Clin Invest 97:133-138, 1996
27. Scrocchi LA, Brown TJ, Maclusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nature Med 2:1254-1258, 1996
28. Edwards CMB, Edwards AV, Bloom SR: Cardiovascular and pancreatic endocrine responses to glucagon-like peptide-1 (GLP-1) in the conscious calf. Exp Physiol 82:709-716, 1997
29. Edwards CMB, Todd JF, Ghatei MA, Bloom SR: Glucagon-like peptide-1 (7-36 amide), a novel treatment for NIDDM (Abstract). QJM 90:715-716, 1997
30. London NJM, James RFL, Bell PRF: Islet purification. In Pancreatic Islet Transplantation. Ricord C, Ed. Austin, TX, Landes, 1992, p. 113-124
31. Bennet WM, Wang ZL, Jones PM, Wang RM, James RF, London NJ, Ghatei MA, Bloom SR: Presence of neuropeptide Y and its messenger ribonucleic acid in human islets: evidence for apossible paracrine role. J Clin Endocrinol Metab 81:2117-2120, 1996
32. Ghatei MA, Uttenlhal LO, Christofides ND, Bryant MG, Bloom SR: Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J Clin Endocrinol Metab 57:488-495, 1983
33. Sarson DL, Bryant MG, Bloom SR: A radioimmunoassay of gastric inhibitory polypeptide in human plasma. J Endocrinol 85:487-496, 1880
34. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR: Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070-1077, 1985
35. 125I-containing acetylating agent. Biochem J 133:529-539, 1973
36. Fehmann HC, Hering B-J, Wolf M-J, Brandhorst H, Brandhorst D, Bretzel RG, Federlin K, Goke B: The effects of glucagon-like peptide-1 (GLP-1) on hormone secretion from isolated human pancreatic islets. Pancreas 11:196-200, 1995
37. Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M: Exendin (9-39) amide is an antagonist of glucagon-like peptide-1 (7-36) amide in humans. J Clin Invest 101:1421-1430, 1998
38. Wheeler MB, Gelling RW, McIntosh CH, Georgiou J, Brown JC, Pederson RA: Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signalling properties. Endocrinology 136:4629-4639, 1995
39. Gremlich S, Porret A, Hani EH, Cherif D, Vionnet N, Froguel P, Thorens B: Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44:1202-1208, 1995
40. Volz A, Goke R, Lankat-Buttgereit B, Fehmann HC, Bode HP, Goke B: Molecular cloning, functional expression, and signal transduction of the GIP receptor cloned from a human insulinoma. FEBS Lett 373:23-29, 1995
41. Starke A, Imamura T, Unger RH: Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration. J Clin Invest 79:20-24, 1987
42. Pipeleers DG, Schult FC, Van-Schravendijk CF, Van-de-Winkel M: Interplay of nutrients and hormones in the regulation of glucagon release. Endocrinology 117:824-833, 1985
43. Muller WA, Faloona GR, Unger RH: The effect of experimental insulin deficiency on glucagon secretion. J Clin Invest 50:1992-1999, 1971
44. Stagner JI, Samols E: Retrograde perfusion as a model for testing the relative effects of glucose versus insulin on the A cell. J Clin Invest 77:1034-1037, 1986
45. Klaff LJ, Taborsky GJ Jr: Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemia. Diabetes 36:592-596, 1987
46. Nightingale JM, Kamm MA, van-der-Sijp JR, Ghatei MA, Bloom SR, Lennard-Jones JE: Gastrointestinal hormones in short bowel syndrome: peptide YY may be the 'colonic brake' to gastric emptying. Gut 39:267-272, 1996
47. Allen JM, Fitzpatrick ML, Yeats JC, Darcy K, Adrian TE, Bloom SR: Effects of peptide YY and neuropeptide Y on gastric emptying in man. Digestion 30:255-262, 1984
48. Schirra J, Roggel R, Leicht P, Wank U, Arnold R, Goke B, Katschinski M: Endogenous GLP-1 (7-36) amide controls endocrine pancreatic secretion and antroduodenal motility in human (Abstract). Gastroenterology 114:A1178, 1998
49. Todd JF, Wilding JPH, Edwards CMB, Khan FA, Ghatei MA, Bloom SR: Glucagon-like peptide-1: a trial of treatment in non-insulin dependent diabetes mellitus. Eur J Clin Invest 27:533-536, 1997